Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Oxford Nanopore; Roche; Thermo Fisher Scientific; NanoLogix; Cell Biosciences; Massachusetts Life Sciences Center

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Nanopore this week said that it is adding 7,000 square feet to its headquarters in the Oxford Science Park in Cambridge, UK, adding to 10,000 square feet of existing labs and offices. The new facility will focus on informatics and be based at Chesterford Research Park.


Roche today said that its cobas KRAS Mutation Test has received the CE Mark and has been launched in Europe for use in helping to guide colorectal cancer treatment. The test identifies mutations in the KRAS gene of colorectal cancer tissue that are predictive of patient response to anti-epidermal growth factor receptor antibody therapies.


Thermo Fisher Scientific this week said that it has presented Judit Villen of the University of Washington, Seattle, with the American Society for Mass Spectrometry (ASMS) 2011 Research Award of $35,000. The award has been sponsored by Thermo Fisher for more than 20 years and is administered by ASMS. It recognizes and supports breakthrough academic research by young scientists in the field of mass spectrometry.


NanoLogix said this week that the US Environmental Protection Agency intends to expand its Cooperative Research and Development Agreement with NanoLogix to include additional water-borne pathogens. The firm said that it will add two scientists to its staff at its Cincinnati laboratory as a result of the contract.


Cell Biosciences has changed its name to ProteinSimple to reflect its core mission in protein research, the firm said this week. The privately-held firm noted that it expects to report revenues of more than $40 million this year.


The Massachusetts Life Sciences Center said that it is now accepting applications for the 2011 Life Sciences Tax Incentive Program, which offers incentives to life science firms conducting research, development, commercialization, and manufacturing in the state. The Center is authorized to award up to $25 million in tax incentives each year. Applications are due by noon on Oct. 7, 2011, and can be submitted on the Center's website.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.